研究文章
血液指标可以用来预测放疗后鼻咽癌患者的甲状腺功能减退的发生率
表2
逻辑回归分析辐射诱导甲状腺功能减退患者170年人大。
|
| 变量(参照组) |
单变量分析 |
多变量分析 |
| 或(95%置信区间) |
价值 |
或(95%置信区间) |
价值 |
|
| 年龄 |
0.98 (0.95 - -1.01) |
0.1354 |
|
|
| 性别男(女) |
0.46 (0.24 - -0.89) |
0.0206 |
0.73 (0.33 - -1.61) |
0.4342 |
| BMI体重不足(与正常) |
0.4 (0.08 - -2.08) |
0.2396 |
|
|
| 超重(体重指数与正常) |
1.16 (0.58 - -2.3) |
0.2438 |
|
|
| T台T2 - 3(与T0 - 1) |
0.73 (0.34 - -1.57) |
0.4248 |
|
|
| N-stage N2 - 3(与N0 - 1) |
2.01 (1.05 - -3.85) |
0.0344 |
1.34 (0.63 - -2.85) |
0.4527 |
| M-stage米1(与米0) |
2.54 (0.61 - -10.49) |
0.1993 |
|
|
| 临床四期(与》) |
0.65 (0.35 - -1.19) |
0.1576 |
|
|
| 新辅助化疗(是的(与) |
1.7 (0.41 - -7.04) |
0.4635 |
|
|
| TPO-Ab |
1.014 (1.003 - -1.026) |
0.0144 |
1.01 (1.002 - -1.03) |
0.025 |
| TG-Ab |
1.004 (1.001 - -1.006) |
0.0024 |
1.004 (1.001 - -1.01) |
0.0112 |
| TG |
1.04 (1.01 - -1.07) |
0.0105 |
1.06 (1.02 - -1.1) |
0.0009 |
| CD19 + |
1.01 (0.94 - -1.09) |
0.7506 |
|
|
| CD3 + |
0.99 (0.97 - -1.02) |
0.4777 |
|
|
| CD4 + |
1.00 (0.97 - -1.03) |
0.9681 |
|
|
| CD8 + |
0.98 (0.95 - -1.02) |
0.3422 |
|
|
| CD4 + / CD8 + |
1.16 (0.82 - -1.63) |
0.4024 |
|
|
| CD38 + |
0.99 (0.92 - -1.06) |
0.7707 |
|
|
| CD45RA - |
1.02 (0.97 - -1.06) |
0.5055 |
|
|
| CD45RA + |
1.00 (0.95 - -1.06) |
0.9631 |
|
|
| CD45RO + |
1.03 (0.98 - -1.07) |
0.2625 |
|
|
| CD45RA +和CD45RO + |
1.05 (0.91 - -1.21) |
0.5254 |
|
|
| CD56 + |
1.01 (0.98 - -1.04) |
0.5395 |
|
|
| 中性粒细胞、淋巴细胞 |
1.02 (0.96 - -1.08) |
0.4844 |
|
|
| EBV DNA |
1 (1 - 1) |
0.3799 |
|
|
| 胆碱酯酶 |
1 (1 - 1) |
0.1324 |
|
|
| 神奇动物 |
1.88 (1.21 - -2.9) |
0.0046 |
1.93 (1.17 - -3.17) |
0.0098 |
|
|
|
|
